X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1710) 1710
Publication (263) 263
Newsletter (34) 34
Magazine Article (15) 15
Newspaper Article (15) 15
Book Chapter (13) 13
Book Review (11) 11
Trade Publication Article (3) 3
Data Set (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1215) 1215
hiv infections - drug therapy (891) 891
atazanavir (836) 836
atazanavir sulfate (814) 814
index medicus (801) 801
male (715) 715
female (640) 640
infectious diseases (633) 633
adult (608) 608
hiv (502) 502
middle aged (495) 495
pharmacology & pharmacy (477) 477
oligopeptides - therapeutic use (398) 398
pyridines - therapeutic use (398) 398
ritonavir (391) 391
antiretroviral therapy (356) 356
protease inhibitors (352) 352
immunology (341) 341
anti-hiv agents - therapeutic use (329) 329
hiv protease inhibitors - therapeutic use (314) 314
pyridines - administration & dosage (303) 303
oligopeptides - administration & dosage (302) 302
drug therapy, combination (289) 289
oligopeptides - adverse effects (283) 283
pyridines - adverse effects (283) 283
lopinavir (280) 280
ritonavir - therapeutic use (278) 278
anti-hiv agents - administration & dosage (259) 259
virology (243) 243
antiviral agents (242) 242
pharmacokinetics (242) 242
tenofovir (241) 241
ritonavir - administration & dosage (236) 236
hiv infections - virology (235) 235
viral load (230) 230
microbiology (226) 226
treatment outcome (226) 226
hiv protease inhibitors - adverse effects (223) 223
anti-hiv agents - adverse effects (215) 215
hiv-1 - drug effects (207) 207
hiv infection (204) 204
hiv protease inhibitors - administration & dosage (202) 202
oligopeptides - pharmacokinetics (201) 201
pyridines - pharmacokinetics (201) 201
drug therapy (196) 196
drug interactions (195) 195
therapy (178) 178
highly active antiretroviral therapy (168) 168
cd4 lymphocyte count (165) 165
efavirenz (162) 162
hiv-infected patients (160) 160
human immunodeficiency virus--hiv (158) 158
hiv protease inhibitors - pharmacokinetics (152) 152
antiretroviral drugs (151) 151
efficacy (151) 151
hiv-1 (150) 150
aids/hiv (145) 145
drug administration schedule (142) 142
dosage and administration (141) 141
anti-hiv agents - pharmacokinetics (140) 140
research (140) 140
ritonavir - adverse effects (140) 140
young adult (134) 134
antiretroviral therapy, highly active (133) 133
pyridines - pharmacology (132) 132
oligopeptides - pharmacology (131) 131
health aspects (130) 130
adenine - analogs & derivatives (129) 129
darunavir (129) 129
virus diseases (128) 128
aged (127) 127
combination (127) 127
emtricitabine (126) 126
lopinavir/ritonavir (126) 126
protease inhibitor (124) 124
safety (122) 122
analysis (121) 121
hiv infections - complications (121) 121
ritonavir - pharmacokinetics (120) 120
active antiretroviral therapy (119) 119
risk factors (117) 117
hiv infections - blood (111) 111
hiv protease inhibitors - pharmacology (108) 108
aids (106) 106
hiv-1-infected patients (105) 105
pyridines - blood (104) 104
infection (103) 103
oligopeptides - blood (103) 103
article (102) 102
care and treatment (102) 102
proteases (100) 100
adolescent (98) 98
human-immunodeficiency-virus (98) 98
infected patients (95) 95
prospective studies (95) 95
antiretroviral therapy, highly active - methods (94) 94
atazanavir sulfate - therapeutic use (93) 93
lamivudine (93) 93
retrospective studies (93) 93
anti-hiv agents (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1690) 1690
Spanish (44) 44
German (29) 29
French (8) 8
Japanese (4) 4
Russian (4) 4
Italian (2) 2
Chinese (1) 1
Korean (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Enfermedades Infecciosas y Microbiología Clínica, ISSN 0213-005X, 2016, Volume 36, Issue 1, pp. 29 - 33
Resumen Objetivo Describir la eficacia en práctica clínica de abacavir, lamivudina y atazanavir sin potenciar (ABC/3TC+ATV) en pacientes pretratados. Pacientes... 
Infectious Disease | Atazanavir sin potenciar | Abacavir/lamivudina + atazanavir | Atazanavir in routine clinical practice | Unboosted atazanavir | Atazanavir en práctica clínica diaria | Abacavir/lamivudine + atazanavir
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, pp. e0123670 - e0123670
Introduction Ritonavir-boosted atazanavir (ATV/r) is a relatively well tolerated antiretroviral drug. However, side effects including hyperbilirubinemia,... 
UNBOOSTED ATAZANAVIR | BILIRUBIN | HYPERBILIRUBINEMIA | EFFICACY | PHARMACOKINETICS | TOLERABILITY | MULTIDISCIPLINARY SCIENCES | ANTIRETROVIRAL THERAPY | RENAL STONES | POLYMORPHISM | RITONAVIR-BOOSTED ATAZANAVIR | Nephrolithiasis - chemically induced | Atazanavir Sulfate - administration & dosage | Humans | Middle Aged | Male | Atazanavir Sulfate - adverse effects | Atazanavir Sulfate - pharmacokinetics | Drug Dosage Calculations | Dyslipidemias - blood | HIV-1 - physiology | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Hyperbilirubinemia - chemically induced | Adult | Female | Hyperbilirubinemia - physiopathology | Nephrolithiasis - physiopathology | Dyslipidemias - diagnosis | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Atazanavir Sulfate - blood | Drug Administration Schedule | Hyperbilirubinemia - diagnosis | HIV-1 - drug effects | HIV Infections - virology | Nephrolithiasis - blood | HIV Protease Inhibitors - administration & dosage | Nephrolithiasis - diagnosis | Antiretroviral Therapy, Highly Active | Hyperbilirubinemia - blood | Dyslipidemias - chemically induced | HIV Infections - drug therapy | Drug Monitoring | Viral Load - drug effects | Dyslipidemias - physiopathology | Highly active antiretroviral therapy | HIV patients | HIV (Viruses) | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Toxicity | Ritonavir | Complications | Dyslipidemia | Lipids | Nephrolithiasis | Dosage | Patients | Side effects | Hyperbilirubinemia | Acquired immune deficiency syndrome--AIDS | Protease inhibitors | Antiretroviral agents | Human immunodeficiency virus--HIV | All terrain vehicles | Index Medicus | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 01/2018, Volume 36, Issue 1, pp. 29 - 33
Objective To describe the experience using the combination abacavir, lamivudine plus non-boosted atazanavir (ABC/3TC+ATV) in a group of pretreated patients.... 
Atazanavir in routine clinical practice | Unboosted atazanavir | Abacavir/lamivudine + atazanavir
Journal Article
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2017, Volume 72, Issue 11, pp. 3163 - 3166
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 06/2015, Volume 93, pp. 267 - 280
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 2011, Volume 154, Issue 7, pp. 445 - 456
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign,... 
Atazanavir | Ritonavir | Research | Drug therapy | Health aspects | Efavirenz | HIV infection
Journal Article
Journal of Clinical Virology, ISSN 1386-6532, 2016, Volume 87, pp. 30 - 36
Journal Article
Drugs, ISSN 0012-6667, 06/2009, Volume 69, Issue 8, pp. 1107 - 1140
Atazanavir (Reyataz®), a protease inhibitor (PI), is approved in many countries for use as a component of antiretroviral therapy (ART) regimens for the... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Pharmacodynamics | Atazanavir | HIV-1 infection | Protease inhibitors | Tolerability | Pharmacokinetics | Antiretroviral therapy | Therapeutic use | STEADY-STATE PHARMACOKINETICS | antiretroviral therapy | pharmacodynamics | NAIVE HIV-1-INFECTED PATIENTS | ONCE-DAILY ATAZANAVIR/RITONAVIR | PROTEASE INHIBITORS ATAZANAVIR | MULTIPLE VIROLOGICAL FAILURES | RITONAVIR-BOOSTED ATAZANAVIR | tolerability | ACTIVE ANTIRETROVIRAL THERAPY | protease inhibitors | pharmacokinetics | IMMUNODEFICIENCY-VIRUS TYPE-1 | PHARMACOLOGY & PHARMACY | TWICE-DAILY LOPINAVIR/RITONAVIR | TOXICOLOGY | EXPERIENCED PATIENTS | therapeutic use | Anti-HIV Agents - pharmacology | HIV Protease Inhibitors - adverse effects | Anti-HIV Agents - adverse effects | Humans | Drug Resistance, Viral | Clinical Trials as Topic | Oligopeptides - adverse effects | HIV Protease Inhibitors - therapeutic use | Oligopeptides - therapeutic use | HIV Protease Inhibitors - pharmacology | Pyridines - adverse effects | Drug Interactions | Atazanavir Sulfate | Adult | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Pyridines - pharmacology | HIV Infections - physiopathology | Oligopeptides - pharmacology | Pyridines - therapeutic use | Usage | Research | Drug therapy | Health aspects | HIV infection | Index Medicus
Journal Article
Journal Article
by Llibre, Josep M and Cozzi-Lepri, Alessandro and Pedersen, Court and Ristola, Matti and Losso, Marcelo and Mocroft, Amanda and Mitsura, Viktar and Falconer, Karolin and Maltez, Fernando and Beniowski, Marek and Vullo, Vincenzo and Hassoun, Gamal and Kuzovatova, Elena and Szlavik, János and Kuznetsova, Anastasiia and Stellbrink, Hans-Jürgen and Duvivier, Claudine and Edwards, Simon and Laut, Kamilla and Paredes, Roger and Losso, M and Kundro, M and Vetter, N and Zangerle, R and Karpov, I and Vassilenko, A and Mitsura, V.M and Paduto, D and Clumeck, N and De Wit, S and Delforge, M and Florence, E and Vandekerckhove, L and Hadziosmanovic, V and Kostov, K and Begovac, J and Machala, L and Jilich, D and Sedlacek, D and Kronborg, G and Benfield, T and Gerstoft, J and Katzenstein, T and Møller, N.F and Pedersen, C and Ostergaard, L and Dragsted, U.B and Nielsen, L.N and Zilmer, K and Smidt, Jelena and Ristola, M and Aho, I and Viard, J.-P and Girard, P.-M and Cotte, L and Pradier, C and Fontas, E and Dabis, F and Neau, D and Duvivier, C and Rockstroh, J and Schmidt, R and Degen, O and Stellbrink, H.J and Stefan, C and Bogner, J and Fätkenheuer, G and Chkhartishvili, N and Kosmidis, J and Gargalianos, P and Xylomenos, G and Lourida, P and Sambatakou, H and Szlávik, J and Gottfredsson, M and Mulcahy, F and Yust, I and Turner, D and Burke, M and Shahar, E and Hassoun, G and Elinav, H and Haouzi, M and Elbirt, D and Sthoeger, Z.M and D'Arminio Monforte, A and Esposito, R and Mazeu, I and Mussini, C and Mazzotta, F and Gabbuti, A and Vullo, V and Lichtner, M and Zaccarelli, M and Antinori, A and Acinapura, R and Plazzi, M and Lazzarin, A and Castagna, A and Gianotti, N and ... and EuroSIDA Study
Medicine (United States), ISSN 0025-7974, 2016, Volume 95, Issue 40, p. e5020
Journal Article